
Kura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.
The payment followed the first patient dosing in the KOMET-017 Phase 3 registrational study for ziftomenib, a novel oral menin inhibitor under development for acute myeloid leukemia (AML).